Altimmune, Inc.

NASDAQ:ALT

Biotechnology

Healthcare
$1.39 +3.09%

+$0.08 today

Market cap
$270.48M
Beta
0.23
P/E (TTM)
-3.7
EPS (TTM)
-$0.73
52W Low $2.56High $7.73

Volume 4.69M

Average 3.81M

ALT Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Altimmune, Inc.NASDAQ: ALT

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit turns negative

Q1 FY2026 gross profit was -$23K, compared with $5K a year earlier. Trailing-twelve-month gross profit was -$14.95M.

Context

  • Gross profit amounted to 100.0% of revenue in FY2025, unchanged from a year earlier.
  • Gross profit increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly gross profit holds near -$23K or moves back toward the trailing-twelve-month quarterly average of -$3.74M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$23K-188.5% QoQ
Last fiscal yearDec 2025
$41K+105.0% YoY
LTMMar 2026
-$14.95M-74835.0% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-560.0%——
1 year+105.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
41K USD
Year-over-year change
+105.0%
4-year CAGR
-68.9%

Gross Profit vs competitors

How ALT compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -74835.0% is the lowest of 6, against a peer median of +137.1%.
  • Gross profit amounts to 41519.4% of revenue for ALT, versus a peer median of 98.3%.
ALT Competitors
Gross Profit for ALT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ABUSArbutus Biopharma CorporationLTM Mar 2026$191.41M USD+1784.1%-29.4%100.0%
VIRVir Biotechnology, Inc.LTM Mar 2026$180.27M USD+137.1%-61.5%275.2%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$68M USD+5.5%-11.0%98.3%
ASMBAssembly Biosciences, Inc.LTM Mar 2026$54.91M USD+621.8%—77.2%
IVAInventiva S.A.FY2025€1.51M EUR-83.6%-55.4%33.7%
INDPIndaptus Therapeutics, Inc.LTM Mar 2026$0 USD———
BMEABiomea Fusion, Inc.LTM Mar 2026-$593K USD———
GPCRStructure Therapeutics Inc.LTM Jun 2026-$1.22M USD———
ALTAltimmune, Inc.LTM Mar 2026-$14.95M USD-74835.0%—41519.4%
Peer median (excluding ALT) —+137.1%-42.4%98.3%

Competitors are the stored peer set for ALT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue4.41M(68K)426K20K41K
Cost of Revenue00000
Gross Profit4.41M(68K)426K20K41K
Gross Margin100.0%100.0%100.0%100.0%100.0%
Research & Development74.54M70.54M65.8M82.23M66.43M
Selling, General & Admin15.41M17.13M18.14M20.97M28.1M
Operating Expenses101.32M87.67M96.36M103.19M94.53M
Depreciation & Amortization551K493K477K238K112K
EBITDA(96.53M)(84.41M)(87.94M)(94.81M)(87.03M)
EBITDA Margin-2189.0%124130.9%-20642.0%-474060.0%-212258.5%
Operating Income(96.91M)(87.74M)(95.93M)(103.17M)(94.49M)
Operating Margin-2197.6%129029.4%-22518.5%-515860.0%-230461.0%
Interest Income203K2.87M7.35M8.07M7.54M
Interest Expense5K8K35K9K1.64M
Other Income / Expenses(176K)2.83M7.48M8.11M5.72M
Income Before Tax(97.09M)(84.91M)(88.45M)(95.06M)(88.77M)
Pre-Tax Margin-2201.6%124867.6%-20762.2%-475295.0%-216522.0%
Income Tax Expense0(197K)00(681K)
Net Income(97.09M)(84.71M)(88.45M)(95.06M)(88.09M)
Net Margin-2201.6%124577.9%-20762.2%-475295.0%-214861.0%
EPS (Basic)(2.35)(1.81)(1.66)(1.34)(1.00)
EPS (Diluted)(2.35)(1.81)(1.66)(1.34)(1.00)
Weighted Avg Shares41.28M46.93M53.25M71M88.1M
Weighted Avg Shares (Diluted)41.28M46.93M53.25M71M88.1M

Altimmune, Inc.

NASDAQ:ALT

Intrinsic Alpha fair value

Locked

Current Price

$1.39

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.